NYSE:PFE 11 May 2026 - 30 June 2026

Pfizer Inc. ticked up on Monday, rising after a move in China increased reimbursement for its GLP-1 offering, giving it another inroad into the market. Shares added 0.4% to $24.37 late in New York trading, but trailed a broader rally. The S&P 500 ended up 1.18% at 7,440.43, and the Nasdaq Composite jumped 2.07%.

Pfizer Inc. shares slid again after its CFO said he’ll step down in August. The stock closed at $25.21, losing 2.7% on Thursday before the Juneteenth holiday and the weekend.

Pfizer shares dropped on Thursday after the drugmaker said finance chief Dave Denton would leave in August, a management change that hit a stock already being judged on a long and expensive growth rebuild.

Pfizer Inc. shares fell in premarket trading Tuesday after the FDA cleared a new label for its hemophilia treatment Hympavzi. Investors are still sizing up the company’s longer path to profits in obesity drugs. The stock traded at $25.62, off 43 cents, or 1.7%.

Acuitas Therapeutics has failed in its attempt to shield Pfizer Inc. and BioNTech’s Comirnaty COVID-19 vaccine from GSK’s patent claims, after a Delaware federal judge tossed the case. Judge Gregory Williams sided with GSK’s subsidiaries, dismissing the Acuitas action for lack of subject-matter jurisdiction. In effect, the court said it didn’t have the authority to hear the suit as filed, leaving the broader patent dispute over the high-profile vaccine unresolved.